Global Animal Drug Compounding Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Animal Drug Compounding market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Animal Drug Compounding market."
Compounding is the mixing of drugs to fit the unique needs of a patient. AHI and AVMA define it as customized manipulation of an approved drug or drugs by a veterinarian, or by a pharmacist upon the prescription of a veterinarian, to meet the needs of a particular patient.
Animal drug shortages are becoming more common and this is unfortunately predicted to worsen in the years ahead, as per official reports published by veterinarians. This shortage encourages the use of widely available compounded drugs to treat a number of animal diseases. A few critical animal drug shortages highlighted by the U.S. FDA are Flunixine Injectable, 35% Perox-Aid, and Epinephrine. To make medical therapy suitable for animal requirements, compounded drugs with the desired active ingredients are unavailable. For e.g., no FDA approved drug for treating megacolon in cats is currently available in the animal drug compounding market. The only safe and effective therapy to treat chronic cat constipation was removed from the U.S. nearly two decades ago. That is why compounding drugs are the only option for veterinarians to treat animals that need pro-kinetic drug therapy.

The global Animal Drug Compounding market is valued at 840 million US$ in 2018 is expected to reach 1370 million US$ by the end of 2025, growing at a CAGR of 6.2% during 2019-2025.
This report focuses on Animal Drug Compounding volume and value at global level, regional level and company level. From a global perspective, this report represents overall Animal Drug Compounding market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Triangle Compounding Pharmacy
    Lorraines Pharmacy
    Medisca
    Diamondback Drugs
    ESSENTIAL PHARMACY COMPOUNDING VET
    ...

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Anti-Infective Agents
    Hormones and Substitutes
    Anti-Inflammatory Agents
    Others

Segment by Application
    Veterinary Hospitals
    Veterinary Clinics
    Veterinary Diagnostic Centers